...
首页> 外文期刊>Oncology letters >NUP214 fusion genes in acute leukemia (Review)
【24h】

NUP214 fusion genes in acute leukemia (Review)

机译:急性白血病中的NUP214融合基因(综述)

获取原文
获取原文并翻译 | 示例

摘要

Nucleoporin 214 (NUP214), previously termed CAN, is required for cell cycle and nucleocytoplasmic transport. The genetic features and clinical implications of five NUP214-associated fusion genes are described in this review. SET-NUP214 was most frequently observed in T-cell acute lymphoblastic leukemia (T-ALL), concomitant with the elevated expression of HOXA cluster genes. Furthermore, the fusion transcript may be regarded as a potential minimal residual disease marker for SET-NUP214-positive patients. Episomal amplifications of NUP214-ABL1 are specific to T-ALL patients. The NUP214-ABL1 gene is observed in ~6% of T-ALL, in children and adults. Targeted tyrosine kinase inhibitors plus standard chemotherapy appear to present a promising treatment strategy. DEK-NUP214 is formed by the fusion of exon 2 of DEK and exon 6 of NUP214. Achieving molecular negativity of DEK-NUP214 is of great importance for individual management. SQSTM1-NUP214 and NUP214-XKR3 were only identified in one T-ALL patient and one cell line, respectively. The NUP214 fusions have significant diagnostic and therapeutic implications for leukemia patients. Additional NUP214-associated fusions require identification in future studies.
机译:细胞周期和核质运输需要核蛋白214(NUP214),以前称为CAN。这篇综述描述了五个与NUP214相关的融合基因的遗传特征和临床意义。 SET-NUP214最常见于T细胞急性淋巴细胞白血病(T-ALL)中,并伴有HOXA簇基因表达升高。此外,对于SET-NUP214阳性患者,融合转录本可以被视为潜在的最小残留疾病标志物。 NUP214-ABL1的游离扩增对T-ALL患者具有特异性。在儿童和成人中,在约6%的T-ALL中观察到NUP214-ABL1基因。靶向酪氨酸激酶抑制剂加标准化疗似乎提出了有希望的治疗策略。 DEK-NUP214由DEK的外显子2和NUP214的外显子6融合而成。实现DEK-NUP214的分子负性对于个人管理非常重要。 SQSTM1-NUP214和NUP214-XKR3仅分别在一名T-ALL患者和一种细胞系中鉴定。 NUP214融合物对白血病患者具有重要的诊断和治疗意义。其他与NUP214相关的融合蛋白需要在未来的研究中进行鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号